BioNTech Sp ADS
BNTX
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
12/26/2024 - 20:00:00
Bid
12/27/2024 - 08:03:23
Bid
Volume
Ask
12/27/2024 - 08:03:23
Ask
Volume
113.77
-0.36 ( -0.32% )
113.10
200
113.88
200
More information
Analysis by TheScreener
24.12.2024
Evaluation Slightly negative  
Interest None  
Sensibility Middle  
Analysis date: 24.12.2024
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 12.11.2024.
Interest
  None
No interest since 24.12.2024.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 26.11.2024 at a price of 118.54.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 20.12.2024), the stock traded below its moving average. The confirmed Technical Reverse (Tech Reverse + 1.75%) point is .
4wk Rel Perf
  -6.37%
 
The four week relative underperformance versus SP500 is 6.37%.
Sensibility
  Middle
The stock has been on the moderate-sensitivity level since 12.11.2024.
Bear Market Factor
  Middle
On average, the stock is likely to decline with the index.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 3.34%.
Mkt Cap in $bn
  27.21
With a market capitalization >$8bn, BIONTECH SE is considered a large-cap stock.
G/PE Ratio
  -0.50
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
  -36.93
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  -18.49%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
  17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  100
For 1% of index variation, the stock varies on average by 1.00%.
Correlation
  0.29
Stock movements are strongly independent of index variations.
Value at Risk
  27.39
The value at risk is estimated at USD 27.39. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  02.07.2021